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A B S T R A C T
Objectives: The aim of this study was to investigate whether quantitative CT image-biomarkers (IBMs) can im-
prove the prediction models with only classical prognostic factors for local-control (LC), regional-control (RC),
distant metastasis-free survival (DMFS) and disease-free survival (DFS) for head and neck cancer (HNC) patients.
Materials and Methods: The cohort included 240 and 204 HNC patients in the training and validation analysis,
respectively. Clinical variables were scored prospectively and IBMs of the primary tumor and lymph nodes were
extracted from planning CT-images. Clinical, IBM and combined models were created from multivariable Cox
proportional-hazard analyses based on clinical features, IBMs, and both for LC, RC, DMFS and DFS.
Results: Clinical variables identiﬁed in the multivariable analysis included tumor-site, WHO performance-score,
tumor-stage and age. Bounding-box-volume describing the tumor volume and irregular shape, IBM correlation
representing radiological heterogeneity, and LN_major-axis-length showing the distance between lymph nodes
were included in the IBM models. The performance of IBM LC, RC, DMFS and DFS models (c-index(vali-
dated):0.62, 0.80, 0.68 and 0.65) were comparable to that of the clinical models (0.62, 0.76, 0.70 and 0.66). The
combined DFS model (0.70) including clinical features and IBMs performed signiﬁcantly better than the clinical
model. Patients stratiﬁed with the combined models revealed larger diﬀerences between risk groups in the
validation cohort than with clinical models for LC, RC and DFS. For DMFS, the diﬀerences were similar to the
clinical model.
Conclusion: For prediction of HNC treatment outcomes, image-biomarkers performed as good as or slightly
better than clinical variables.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is primarily
managed by surgery and/or radiotherapy (RT) with or without systemic
treatment. At present, the 5-year overall survival rate is around 60%
[1]. However, 30%-50% of patients with locally advanced HNSCC still
experience treatment failures, predominantly occurring at the site of
the primary tumor, followed by regional failures and distant metastases
[2]. Risk assessment of local control (LC), regional control (RC), distant
metastasis-free survival (DMFS) and disease-free survival (DFS) of
HNSCC patients becomes increasingly important to optimise treatment
[3–7]. For HNSCC patients, molecular-based factors such as human
papilloma-virus (HPV) [3,4] and patient-speciﬁc factors such as age and
World Health Organization performance-status (WHO PS) have been
identiﬁed as prognostic clinical factors for LC, RC, DMFS and DFS [5–7].
However, these clinical factors are not suﬃcient for identifying patients
that will beneﬁt most from speciﬁc treatment strategies. For this pur-
pose, more detailed information is required, including factors that re-
ﬂect the characteristics of the whole tumor, such as tumor volume,
shape and heterogeneity [8–16].
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A wide variety of medical images is generated for diagnostic and
staging purposes, such as TNM staging. In current clinical practice,
these images are used for guiding treatment decision-making [3].
Image-biomarkers (IBMs) may also be extracted from these medical
images, transforming image data into quantitative information that
describes intensity, shape and textural characteristics of the whole
tumor. IBMs can provide more spatial and textural information about
tumor features than TNM staging [8–10]. For patients treated with
primary non-surgical modalities, like (chemo)radiotherapy, where only
limited pathological information is available, the use of image-bio-
markers might improve the prediction of treatment outcomes and im-
prove medical decision-making [9].
IBMs have demonstrated their value to predict treatment outcome
and complications for patients with head and neck, lung, breast, pan-
creatic, and colorectal cancers [9,11–16]. In a previous study, we
showed that the quantitative computed-tomography (CT) IBMs were
good substitutes for the qualitative clinical variable N-stage, and that
they improved the performance of multivariable prediction models for
overall survival, compared to models consisting of clinical variables
alone [17]. The next challenge is to ﬁnd IBMs that allow for a better
prediction of local-regional failure and distant metastasis. Based on our
previous study, we hypothesized that IBMs would provide similar or
better predictive information than clinical variables for LC, RC, DMFS
and DFS. The aim of this study was to investigate whether multivariable
prediction models for LC, RC, DMFS and DFS, consisting of both clinical
variables and IBMs perform better than prediction models with only
classical prognostic factors.
Materials and Methods
Patient selection and treatment
This was a retrospective analysis in a prospective cohort study,
which was composed of 707 consecutive non-surgically treated HNSCC
patients. The tumors originated in the oral cavity, oropharynx, naso-
pharynx, hypopharynx or larynx and were primarily treated with de-
ﬁnitive radiotherapy at the University Medical Center Groningen be-
tween July 2007 and December 2015. We excluded 202 patients
without contrast-enhanced planning CT-scans, 45 patients with metal
or motion artifacts in the region of the primary tumor (PT) or positive
lymph nodes (LN), and 16 patients with previous neck dissection.
Overall 444 patients with standard contrast-enhanced planning CT-
scans (Somatom Sensation Open, Siemens, Forchheim, Germany; voxel
size: 1.0× 1.0× 2.0mm; scan voltage: 120 kV; and convolution
kernel: B30) were included. Overall 240 patients treated before June
2012 were enrolled in the training cohort and 204 patients treated after
June 2012 in the validation cohort. All patients were treated with de-
ﬁnitive three-dimensional conformal radiotherapy (3D-CRT), intensity-
modulated radiotherapy (IMRT) or volumetric modulated arc therapy
(VMAT) to a total dose of 70 Gy with fractions of 2 Gy in 6–7weeks,
with or without chemotherapy or cetuximab. Detailed radiation pro-
tocols have been published previously [17,18].
Clinical parameters
Clinical parameters including age, gender, TNM-stage, clinical
stage, treatment modality and WHO PS were collected from our pro-
spective data registration program. TNM and clinical stage were de-
ﬁned according to the 7th edition of the American Joint Committee on
Cancer Staging Manual [3]. Tumor site was included in the analysis,
and tumors originating in the oropharynx were further stratiﬁed by
HPV status as HPV-positive, HPV-negative and HPV-unknown
(Table 1). HPV-status was assessed by p16 immunohistochemistry fol-
lowed by DNA polymerase chain reaction in cases of p16-positivity in
OPC patients. Tumor volume was included in the analysis as a geo-
metric IBM, and not as a clinical parameter.
CT image-biomarkers
An overview of the IBM extraction process and analysis is shown in
Fig. 1. The IBMs were extracted using in-house developed Matlab based
software (version R2014a; Mathworks, Natick, USA). For a more de-
tailed description of the IBMs, we refer to previous work [11] and
Supplementary A. All IBMs were reported complying with the REMARK
guidelines [19] and IBM formulas are in line with the “Image biomarker
standardisation initiative” [10].
CT intensity and geometric IBMs
The primary tumor (PT) and pathological lymph node (LN) were
delineated on the planning CT-scans by experienced head and neck
radiation oncologists. Thirty-six intensity and 40 geometric IBMs were
extracted from both the PT and LN. All IBMs from LN were marked as
LN_IBMs. The intensity IBMs were obtained from the histogram of the
voxel intensities of the delineated structures, e.g. mean represents the
average voxel intensity and the skewness quantiﬁes the degree of
asymmetry around the mean value. The geometric IBMs, such as vo-
lume, bounding-box-volume and major-axis-length, were extracted
Table 1
Characteristics of the head and neck squamous cell carcinoma patients in the
training and validation cohorts.
Training Cohort Validation Cohort p-Value
Characteristics n= 240 % n=204 %
Age at diagnosis
(mean ± SD, years)
62 ± 10 63 ± 9 0.351b
Gender 0.779c
Male 176 73.3 152 74.5
Female 64 26.7 52 25.5
T-stagea 0.839c
T1 27 11.3 25 12.3
T2 70 29.2 52 25.5
T3 73 30.4 67 32.8
T4 70 29.2 60 29.4
N-stagea 0.708c
N0 85 35.4 78 38.2
N1 28 11.7 21 10.3
N2 117 48.8 100 49.0
N3 10 4.2 5 2.5
Clinical stagea 0.451c
I 16 6.7 12 5.9
II 41 17.1 27 13.2
III 46 19.2 50 24.5
IV 137 57.1 115 56.4
Treatment modality
RT only 123 51.3 114 55.9
RT with systemic treatment 117 48.8 90 44.1
WHO PS 0.931c
0 163 67.9 136 66.7
1 65 27.1 56 27.5
2 10 4.2 9 4.4
3 2 0.8 3 1.5
Tumor site (with HPV
status)
0.078c
Oral cavity 14 5.8 13 6.4
HPV-positive oropharynx 25 10.4 29 14.2
HPV-negative oropharynx 57 23.8 50 24.5
HPV-unknown oropharynx 3 1.3 8 3.9
Nasopharynx 4 1.7 7 3.4
Hypopharynx 37 15.4 16 7.8
Larynx 100 41.7 81 39.7
Abbreviations: T= tumor; N= lymph node; RT= radiotherapy; WHO
PS=World Health Organization performance status; HPV=human papilloma
virus status.
a According to the 7th edition of the AJCC/UICC staging system.
b p-Value was calculated using the independent sample t-test.
c p-Value was calculated using the chi-square test.
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from the three-dimensional (3D) contoured structures. The LN_IBMs
from patients without lymph node metastasis were deﬁned as 0.
CT textural IBMs
Forty-four textural CT IBMs describing the radiological hetero-
geneity of the PT tissue were derived from three diﬀerent matrices: the
gray level co-occurrence matrix (GLCM) [20], the gray level run-length
matrix (GLRLM) [21] and the gray level size-zone matrix (GLSZM) [22].
Those matrices provide a statistical view of image texture based on the
relationship between neighbouring pixels. GLCM IBMs describe the
number of voxel transitions of certain gray levels, e.g. the IBM corre-
lation is larger in case of larger areas of similar gray levels. GLRLM
IBMs assess the number of directional gray level repetition, e.g. low run
length non-uniformity means consecutive voxels with the same gray
level are distributed homogeneously. The GLCM and GLRLM IBMs were
computed from each 3D directional matrix and averaged over 13 di-
rections. GLSZM quantiﬁes the volumetric gray level repetition, e.g.
small zone emphasis depends on the occurrence of small zone. A higher
value indicates to the ﬁne texture and a lower value corresponds to the
coarse texture. GLSZM IBMs were computed from a 3D matrix.
Endpoints
The endpoints were LC, RC, DMFS and DFS. The events of LC and RC
were deﬁned as recurrent or residual disease within or adjacent to the
primary site and regional nodes, respectively. The events of DMFS were
deﬁned as distant metastasis. Events for DFS is deﬁned as any events
mentioned above or death due to any causes. Time to event was deﬁned
as the date from the ﬁrst day of radiotherapy until the date of the event.
Patients without failures were censored at the date of last follow-up.
Patients received systematic follow-up every 3months in the ﬁrst year
following treatment and every 6months thereafter.
Data analysis
Step 1: Clinical models
Clinical factors that were considered as candidate predictors in-
cluded categorical variables: gender (female vs. male), T-stage (T3-T4
vs. T1-T2), N-stage (N2-N3 vs. N0-N1), clinical stage (IV vs. I-III),
treatment modality (radiotherapy with systemic treatment vs. radio-
therapy only), WHO PS (1–3 vs. 0), tumor site combined with HPV
status (nasopharynx vs. larynx vs. HPV-positive oropharynx vs. hypo-
pharynx vs. oral cavity vs. HPV-negative oropharynx), and one con-
tinuous variable: age.
Univariable analysis was performed to assess risk factors for LC, RC,
DMFS and DFS. In the training cohort, all factors were included in a
multivariable Cox proportional hazard regression analysis (forward
selection based on Likelihood ratio test, p < 0.05) to create multi-
variable clinical models. The entire process was repeated in 1000
bootstrap samples and only the most frequently selected variables were
considered in the ﬁnal clinical model.
Step 2: IBM models
Twenty patients from the training cohort were used for the eva-
luation of the inter- and intra-observer reproducibility. For each pa-
tient, the IBMs were extracted from two delineations by two radiation
oncologists and two delineations within 6months by one radiation
oncologist. The interclass correlation coeﬃcient (ICC) of IBMs larger
than 0.70 were considered to be robust for delineation variation, and
were included in the further analysis.
To reduce the probability of overﬁtting and multicollinearity, pre-
selection was performed for IBMs. All IBMs were analyzed as con-
tinuous variables, if the Spearman rank correlation (ρ) between pairs of
IBMs was > 0.80, then the IBM with the lower univariable association
with the endpoint was excluded from further analysis [23,24]. After
pre-selection, multivariable Cox proportional hazard regression ana-
lysis was used to develop multivariable IBM models.
The entire process of pre-selection and model development was
repeated in 1000 bootstrap samples, and only the most frequently se-
lected variables were included in the ﬁnal IBM models. The same
methodology was used for combined models described below.
Step 3: Combined models
All clinical factors and IBMs were included in the multivariable
analysis to create combined models. The same bootstrapping metho-
dology including pre-selection and model development described in
step 2 was used to build ﬁnal combined models.
Step 4: Model performance in the training and validation cohorts
The concordance index (c-index) was determined to assess the
models’ discriminative power and the z-score test was used to test the
signiﬁcance of c-index diﬀerences. Internal validation (bootstrapping)
was used for the variable selection, and accordingly correction for op-
timism of coeﬃcients and c-indexes according to the TRIPOD statement
[25].
The performance of the corrected ﬁnal clinical, IBM and combined
models were then tested in the validation cohort. Patients in the vali-
dation cohort were stratiﬁed into two risk groups based on the models:
a low-risk group with hazard values≤the median and a high-risk group
with hazard values> the median. Kaplan-Meier curves were generated
to analyze LC, RC, DMFS and DFS rates for the low- and high-risk groups
and Log-rank tests were used to compare the diﬀerences.
The chi-square test was used to compare the categorical variables
and an independent sample t-test was used to compare normally dis-
tributed variables between diﬀerent groups. Two tailed p-values< 0.05
were considered statistically signiﬁcant. Statistical analysis was per-
formed using the R software (version 3.2.1). The R-package survival
(version 2.41–3) was used for modeling.
Results
For the training cohort, the median follow-up times for LC, RC,
DMFS and DFS were 48.2, 49.7, 50.3 and 45.2 months, respectively.
Overall, 56 (23%) local recurrences, 38 (16%) regional recurrences, 34
Fig. 1. The image-biomarkers (IBMs) extraction and analysis workﬂow.
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(14%) distant-metastases and 137 (57%) events occurred for LC, RC,
DMFS and DFS. For the validation cohort, the median follow-up times
for LC, RC, DMFS and DFS were 21.0, 21.1, 22.5 and 20.3 months. In
total 35 (17%), 23 (11%), 20 (10%) and 68 (33%) events were observed
for LC, RC, DMFS and DFS. The clinical characteristics of the training
and validation cohorts in this study are listed in Table 1. No signiﬁcant
diﬀerences between the two datasets were found regarding the baseline
characteristics.
Step 1: Clinical models
Univariable analysis showed weak associations between tumor site
(combined with HPV status) and endpoints. Therefore, the variable
tumor site was analysed as a composite variable by combining diﬀerent
tumor sites. Similar associations with the endpoints were found for
nasopharyngeal cancer, HPV-positive OPC and laryngeal cancer in this
cohort, which is in line with the results of other studies [26–28]. Hence,
tumor sites with worse treatment outcomes were grouped together to
compare with the group of tumor sites which had favorable treatment
outcomes (composite tumor site: hypopharynx, oral cavity and HPV-
negative oropharynx vs. nasopharynx, larynx and HPV-positive or-
opharynx) [2,4,7,26–28]. Using this stratiﬁcation, the composite tumor
site was signiﬁcantly associated with LC, RC, DMFS and DFS
(p= 0.006, 0.002, 0.001,< 0.001).
A number of other clinical parameters showed signiﬁcant associa-
tions with outcomes in the univariable analysis. They are shown in
Supplementary B.
In the multivariable clinical analysis (Table 2), composite tumor site
was identiﬁed as an independent signiﬁcant prognostic feature for LC,
DMFS and DFS. Next to composite tumor site, WHO PS was associated
with LC, and clinical stage and WHO PS were associated with RC. N-
stage was a signiﬁcant prognostic factor for DMFS, while WHO PS and
age were associated with DFS.
Step 2: IBM models
The average of the inter- and intra-observer agreement of all IBMs
was 0.90 and 0.88, showing the stability of contouring was reasonably
good. The ICC value for the inter-observer and intra-observer agree-
ment was higher than 0.7 for 91% and 89% of the radiomic features and
only the IBMs with an ICC greater than 0.7 were included in the further
analysis.
According to the variable selection frequency plot (Supplementary
C), the following IBMs were most frequently selected and signiﬁcantly
associated with the endpoints in the multivariable analyses for LC:
correlation of GLCM; for RC and DMFS: bounding-box-volume and
LN_major-axis-length, and for DFS: bounding-box-volume and correla-
tion of GLCM (Table 2).
Step 3: Combined models
The coeﬃcients and variables of the ﬁnal combined models are
depicted in Table 2. Composite tumor site and correlation of GLCM
were selected with a comparable frequency as independent prognostic
factors for the combined LC and DFS models (Frequency plot in Sup-
plementary C). Correlation of GLCM was found to be signiﬁcantly as-
sociated with composite tumor site (p < 0.001, logistic regression
analysis), therefore any one of these could be included in the model,
and performed similarly. For this study, only the feature with the larger
frequency was included in the combined model. Therefore, correlation
of GLCM was included in the LC-model and composite tumor site in the
DFS-model. No clinical variables were selected into the combined RC
model. The combined RC and DMFS models containing bounding-box-
volume and LN_major-axis-length showed better performance than
models containing clinical stage and N-stage for RC and DMFS.
Step 4: Model performance and external validation
The performances of the clinical, IBM and combined models in the
training and validation cohorts are outlined in Fig. 2. The clinical
models’ prediction performances in the training cohort were as follows,
with the 95% conﬁdence-interval (CI)), LC: 0.64 (0.56–0.71), RC: 0.74
(0.64–0.83), DMFS: 0.71 (0.62–0.81) and DFS: 0.66 (0.61–0.72). The
performances of IBM models were comparable to that of the clinical
models. The combined models, performed as good as or signiﬁcantly
better than the clinical models, with c-indexes of 0.66 (0.58–0.74, z-
score test: p= 0.23) for LC, 0.78 (0.67–0.88, p=0.13) for RC, 0.72
(0.62–0.82, p= 0.36) for DMFS and 0.69 (0.64–0.74, p= 0.004) for
DFS in the training cohort and performed well in the validation cohort
with c-indexes of 0.64 (0.55–0.73), 0.80 (0.73–0.87), 0.71 (0.58–0.85)
and 0.70 (0.63–0.76) for LC, RC, DMFS and DFS, respectively.
Fig. 3 shows the Kaplan-Meier curves for low- and high-risk groups
in the validation cohort, stratiﬁed according to their median hazard
value. When patients were stratiﬁed with the combined models
(Fig. 3b,d,f,h), the diﬀerences between the curves were larger than with
all clinical models (Fig. 3a,c,e,g) except for DMFS. The actual prob-
abilities of LC, RC, DMFS and DFS at 2-year in low- and high-risk groups
are shown in Supplementary D. Using combined models resulted in a
more distinct risk group classiﬁcation than using models based on
clinical variables only for LC, RC and DFS. For example, the 2-year LC
diﬀerence between the low- and high-risk groups improved from 8.6%
with the clinical model to 14.3% with the combined model, and the
hazard ratio improved from 2.0 to 2.6.
Discussion
This study showed a detailed analysis on the diﬀerent patterns of
failure by evaluating LC, RC, DMFS and DFS for HNC patients primarily
treated with radiotherapy. Firstly, all clinical variables were explored
thoroughly to build optimal clinical models for comparison [29]. Sec-
ondly, the quantitative IBMs were included in the models and provided
similar information as qualitative clinical variables. Finally, combined
models showed slightly better performance or as good performance as
clinical and IBM models in this study.
Clinical models were developed based on clinical parameters alone.
HPV status, as a conﬁrmed signiﬁcant prognostic factor in OPC patients,
was combined with tumor site in the analysis [4,27,28] (Table 1).
However, no strong associations between tumor site and endpoints
were found in the univariable analysis. In order to obtain the optimal
clinical models, the composite tumor sites with similar associations
with endpoints were grouped together, and showed signiﬁcant asso-
ciations with LC, RC, DMFS and DFS [2,4,7,26]. The other clinical
prognostic factors (WHO PS, clinical stage, N-stage and age) in our
study are in line with those found by other investigators [27–33].
Several IBMs were identiﬁed as independent prognostic factors in
the ﬁnal IBM models, two geometric and one textural. These included:
bounding-box-volume, the LN_major_axis_length and correlation of
GLCM. With only one or two IBMs, the IBM models performed as well as
the clinical models.
The bounding-box-volume refers to the volume of the smallest cube
that encloses all pixels of the contoured tumor. Generally, a larger
bounding-box-volume indicates a more invasive, irregular-shaped and
larger tumor, and was indeed associated with worse RC and DFS in our
study. IBM models with bounding-box-volume as the only variable
could achieve c-indexes of 0.77 and 0.66 in predicting RC and DFS,
which were already comparable with the performances of clinical
models. When bounding-box-volume was added to clinical models, it
performance better than clinical stage in modelling RC and signiﬁcantly
improved the DFS model (p=0.004, Table 2).
Since tumor volume was a prognostic factor for overall survival for
HNSCC patients with advanced stage, tumor volume was also included
in the analysis as a geometric IBM [5,8,34,35]. Tumor volume was a
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signiﬁcant prognostic factor in the univariable analysis for RC, DMFS
and DFS. It was strongly correlated with bounding-box-volume
(ρ=0.95), but performed slightly worse than bounding-box-volume in
predicting RC, DMFS and DFS in this study. The diﬀerence between the
bounding-box-volume and tumor volume is that bounding-box-volume
includes information on both tumor volume and shape (Fig. 4a and b).
The tumor volumes in Fig. 4a and b were similar, but the bounding-box-
volume of Fig. 4b had an irregular shape, and was twice as large as that
of Fig. 4a. Tumor volume depends on the doubling time of tumor cells,
while tumor shape is caused by invasive growth patterns. Our result
suggests that the bounding-box-volume is more relevant for the RC and
DFS than tumor volume.
LN_major-axis-length describes the largest distance between any
two voxels of the positive lymph node(s) (Fig. 4c and d), which is the
most selected IBM of RC and DMFS IBM models (Supplementary C).
When the patient has only one lymph node, LN_major-axis-length re-
presents the size of the LN. When the patient has more than 1 lymph
node, it means the largest distance between two distant lymph nodes. A
larger LN_major-axis length is not only related to the size of the pa-
thological lymph nodes but also to the distance between them, which
might indicate more aggressive behavior of the tumor cells. LN_major-
axis-length showed a spearman rank correlation of 0.80 with N-stage.
However, LN_major-axis-length performed better than N-stage in the
prediction of RC and DMFS, and N-stage did not add prognostic in-
formation to the model with LN_major-axis-length. This observation
was supported by our previous study on overall survival, in which
LN_major-axis-length had a stronger association with overall survival
than N-stage [17]. The LN_major-axis length reﬂects not only N-stage
information (size and location) but also patterns of growth. Therefore,
it is advantageous to use LN_major-axis length as a surrogate for N-
stage.
Correlation was selected as a prognostic IBM for LC and DFS. A
lower correlation value indicates a higher radiological homogeneity,
which was associated with improved LC and DFS in our study (Fig. 4e
and f). This observation is supported by the ﬁndings of Haralick et al.,
showing that correlation was suitable for distinguishing heterogeneous
and homogeneous materials [17,20,36]. There are other IBMs which
are also used to quantify the intra-tumor heterogeneity and homo-
geneity on a millimeter scale, such as run length non-uniformity and
gray level non-uniformity. These IBMs demonstrate prognostic perfor-
mance for overall survival in HNC [9,17]. The intra-tumor
heterogeneity is caused by multiple coexisting sub-clonal populations in
the tumor [36,37]. The association between cellular information and
IBMs may explain the performance of IBMs in survival analysis. Further
research is necessary to investigate the underlying mechanisms and to
identify IBMs representing tumor radiological heterogeneity for dif-
ferent endpoints. Our study found that the correlation of GLCM was
signiﬁcantly associated with the composite tumor site (p < 0.001).
This association could be explained by the higher homogeneous tissue
density in HPV-positive OPC, laryngeal and nasopharyngeal cancers,
compared with other tumor sites. This hypothesis should be explored
and these models might be improved with the addition of subgroup
analysis in diﬀerent head and neck tumor locations.
The advantage of using IBMs is that they provide quantitative and
objective information compared with traditional medical image ana-
lysis. Furthermore, on the basis of non-invasive medical imaging, IBMs
could be used to assess the characteristics of tumor tissue. In this study,
it was shown that CT IBMs performed as well as clinical features in
predicting treatment outcomes. It is expected that IBMs extracted from
more advanced imaging techniques would provide more tumor-speciﬁc
information. Therefore, more studies on IBMs from advanced imaging
techniques is recommended, to improve risk stratiﬁcation for HNSCC.
However, the variations in imaging protocols, segmentation, feature
selection and modelling between diﬀerent institutes may reduce the
reproducibility, robustness and clinical utility. Standardization of the
extraction of IBMs and report guidelines have been proposed and must
be followed [29]. Furthermore, validation of IBMs on large external
datasets is needed to ensure widespread acceptance.
The prediction models we described can be used to identify patients
with a high risk of recurrence and metastasis prior to deﬁnitive (chemo-
)radiation. Close imaging follow up for high risk patients after treat-
ment can be suggested in cases when salvage surgery is applicable.
Furthermore, dose intensiﬁcation and more aggressive adjuvant treat-
ment are options for high risk patients. These options should be in-
vestigated in order to guide future personalized strategies aimed at
improving treatment outcome. Whether this model is applicable to HNC
patients treated with surgery is not discussed in this paper.
Conclusion
Models containing quantitative image-biomarkers describing the
volume, irregular shape and radiological heterogeneity of the tumor
Fig. 2. Prediction performance of clinical, IBM and combined models. Abbreviation: LC: local control; RC: regional control; DMFS: distant metastasis-free survival;
DFS: disease-free survival; IBM: image-biomarker.
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and the distance between lymph nodes performed as good as clinical
variables in predicting treatment outcomes for HNC patients. These
image-biomarkers are worth exploring in future studies to determine
whether they can improve the clinical approaches currently employed.
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Fig. 3. Kaplan-Meier curves of high (hazard values>median) and low (hazard values ≤median) risk groups stratiﬁed by clinical and combined models. When the
patients are stratiﬁed with the combined models (b,d,f,h), the LC, RC, DMFS and DFS curves separation and hazard ratio (>median vs.≤median) between diﬀerent
risk groups are larger than or similar as clinical models (a,c,e,g). Abbreviation: LC: local control; RC: regional control; DMFS: distant metastasis-free survival; DFS:
disease-free survival; HR=hazard ratio; CI= conﬁdence interval.
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